Every cancer patient deserves the right treatment
for their individual form of cancer.
New The power of precision, For Every Oncologist, Today
With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality.
Outcome of the IndiTreat clinical trial (TICC) is published by ASCO prior to its Annual Meeting in June 2021.
For over 2 decades, testing cancer treatments on microtumors rather than on the patient has been on the horizon. With IndiTreat®, 2cureX makes microtumor testing an operational reality to serve you and your cancer clinic.
IndiTreat CE IVD is available today for identifying effective chemotherapies of certain forms of colorectal cancer if a biopsy is feasible. Ask your doctor if it is possible to consider IndiTreat for your cancer.
2cureX Newsletter – ASCO update
ASCO Update – New Treatment strategy prolongs progression free survival in colorectal cancer patients
Redeye releases an updated 2cureX Equity Research Report
2curex update at Life Science Investor Conference, ØU Life Science Copenhagen 26/05’21
Get notified on mail, when news or press release is posted on our website